세계 우울증 치료제 시장 – 2024-2031

Overview
Global dysthymia drugs market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Dysthymia is often characterized by chronic depression for at least two years and includes lowered energy, appetite, sleep disturbances and low self-esteem. Anti-depressants are drugs that inhibit the reuptake of neurotransmitters through selective receptors, thereby increasing the concentration of specific neurotransmitters around the nerves in the brain.
Several classes of medications are used to treat dysthymia, with Selective Serotonin Reuptake Inhibitors (SSRIs) being the first-line treatment.
Market Dynamics: Drivers & Restraints
Increasing awareness about mental illness
Individuals with dysthymia are more likely to seek professional care as mental health is less stigmatized and people are more open about their issues. This can result in a considerable increase in diagnoses and prescriptions for drugs like SSRIs, which are the first-line treatment for dysthymia. As awareness grows, so does our understanding of therapeutic choices.
People may be more willing to use dysthymia medication if they perceive it as a typical and helpful strategy to manage their mental health. This can reduce drug reluctance while increasing patient adherence to treatment strategies. Increased mental health awareness initiatives can help people recognize the symptoms of dysthymia, an illness that is often underestimated. This can result in earlier diagnoses and actions, possibly including medication use. Thus, increasing awareness among individuals is expected to drive the market growth.
Longer approval time and clinical trials of antidepressant drugs
The long process of drug approvals and stringent regulations are expected to hamper the growth of the market. Therefore, they have been cautious of stretching trial results beyond their limited capacity to inform clinical practice as trials are not representative of real-world patients or medication management practices. There is a substantial need to develop more realistic models to evaluate the clinical utility of antidepressants.
For more details on this report – Request for Sample
Segment Analysis
The global dysthymia drugs market is segmented based on drug, distribution channel and region.
Selective Serotonin Reuptake Inhibitor (SSRI) segment is expected to dominate the market growth
Selective Serotonin Reuptake Inhibitor (SSRI) is expected to hold the major position in the market share due to various factors. Doctors recommend SSRIs as the first-line treatment for dysthymia. SSRIs have been demonstrated to effectively treat dysthymia's fundamental symptoms, which include low mood, loss of interest in activities, exhaustion, and difficulties concentrating.
Most patients tolerate SSRIs well, and they have fewer side effects than other drugs used to treat dysthymia, such as tricyclic antidepressants. SSRIs have a long history of use to treat depression and other diseases, therefore their safety profile is well known. Many generic versions of SSRIs are now accessible, making them a less expensive option for patients. SSRIs are expected to maintain their dominance in the dysthymia medication market.
Researchers are constantly creating new SSRIs with potentially lower side effects and higher efficacy. Furthermore, as the emphasis on mental health grows, more persons with dysthymia are expected to seek therapy, driving up demand for SSRIs. Thus, the above factors are expected to hold the segment in the dominant position during the forecast period.
Geographical Analysis
North America is expected to hold a significant position in the dysthymia drugs market share
North America, particularly the United States, has a higher prevalence of dysthymia than other regions. Increased awareness of mental health diseases has been contributing to this discovery, as people are more inclined to seek care for mental health issues. Dysthymia is more prevalent among older persons.
North America's geriatric population is expanding, which indicates that more people are expected to have the illness. Mental health coverage is becoming increasingly widespread in North American health insurance plans. This makes dysthymia treatment, including drugs, more affordable.
For instance, according to the National Institute of Health report in 2024, it is estimated that around 19.1% of U.S. adults had any anxiety disorder in the past year. An estimated 31.1% of U.S. adults experience any anxiety disorder at some time in their lives.
Additionally, according to the Anxiety & Depression Association Social Anxiety Disorder (SAD) in 2022, stated that anxiety disorder affects 15 million adults which is approximately 7.1% of the U.S. population each year. SAD is equally common among men and women and typically begins around age 13.
COVID-19 Impact Analysis
The COVID-19 pandemic and the resulting economic collapse have negatively affected many people’s mental health and created new barriers for people already who have mental illness and substance use disorders. It was majorly attributed to the increased exposure to stress due to job loss and social isolation. The patients with dysthymia drugs did not prefer the hospital for the treatment; instead, they took the prescribed medicines online. Moreover, the pandemic has affected various phases of the market, such as production, development, and drug supply, and affected the growth of various companies due to lockdowns implemented by many governments worldwide.
Market Segmentation
By Drug
• Selective Serotonin Reuptake Inhibitor (SSRI)
o Citalopram
o Fluvoxamine
o Paroxetine
o Fluoxetine
• Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
o Duloxetine
o Bupropion
o Venlafaxine
• Tricyclic Antidepressant (TCA)
o Nortriptyline
o Desipramine HCl
o Mirtazapine
• Monoamine Oxidase Inhibitor (MAOI)
o Isocarboxazid
o Phenelzine
o Selegiline
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., GSK Plc, Elikem Pharmaceuticals Pvt Ltd , Taj Pharmaceuticals Limited, Neuracle Lifesciences, Wellona Pharma, Mallinckrodt Pharmaceuticals and Teva Pharmaceuticals USA, Inc. among others.
Why Purchase the Report?
• To visualize the global dysthymia drugs market segmentation based on product, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of dysthymia drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global dysthymia drugs market report would provide approximately 53 tables, 47 figures and 176 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies